The World Health Organization has recommended an urgent clinical trial in the Democratic Republic of Congo to test the Ervebo vaccine against the Bundibugyo strain of Ebola. Ervebo, the only licensed Ebola vaccine, has shown effectiveness against other strains but requires evaluation for this emerging threat. The trial aims to accelerate containment efforts as health authorities race to prevent further spread in a region already battling multiple health crises.
The World Health Organization’s Technical Advisory Group on Vaccine Research has called for a clinical trial in the Democratic Republic of Congo to assess the Ervebo vaccine’s efficacy against the Bundibugyo virus, a less common but dangerous strain of Ebola. Ervebo, developed by Merck and approved in 2019, is currently the only licensed vaccine for Ebola Zaire, the most widespread strain. While it has proven effective in previous outbreaks, its performance against Bundibugyo remains untested in real world settings.
The decision comes as Congo faces a resurgence of Ebola, compounded by ongoing challenges like armed conflict, weak healthcare infrastructure, and concurrent outbreaks of measles and cholera. The WHO is collaborating with local health authorities, Gavi the Vaccine Alliance, and other partners to launch the trial swiftly, though logistical hurdles may delay implementation.
DISCUSSION (0)